This trial is active, not recruiting.

Condition breast cancer
Collaborator Arbeitskreis Klinische Studien
Start date February 2007
End date June 2019
Trial size 4500 participants
Trial identifier NCT01351584, IOM TMK, Tumorregister Mammakarzinom


The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Course of Antineoplastic Treatment
time frame: 5 years

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Breast cancer - 18 years and older - Antineoplastic or antihormonal treatment Exclusion Criteria: - No breast cancer - Below 18 years - No antineoplastic or antihormonal treatment

Additional Information

Official title Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany
Description The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by iOMEDICO AG.